Spago Nanomedical AB (publ) announced the publication of four new patent applications filed with the European Patent Office (EPO) to expand and extend the patent protection for the company's radionuclide therapy Tumorad. If granted, Tumorad will receive protection in all strategically key markets, including the EU, US and Japan, until at least 2042. The applications relate to composition patents and together they cover the various key components of the drug candidate 177Lu-SN201.

Recently, Spago Nanomedical received approval to start a first clinical phase I/IIa study with the drug candidate 177Lu- SN201 in cancer patients and the first patient is expected to be included shortly.